beta-Phellandrene is a monoterpene hydrocarbon found in angelica root, dill, elemi, fir, ginger, parsley herb, pine, tangerine, and yuzu profiles in the AromaForge archive. The public evidence is strongest for identity, biosynthesis, and fragrance-safety evaluation, while direct isolated-compound bioactivity evidence remains limited and mixed. That makes beta-phellandrene best described as a recurrent aroma and chemotaxonomic marker with early enzyme and toxicology data, not as a clinically validated wellness-active.
Chemical identity and composition
PubChem lists beta-phellandrene as C10H16 with IUPAC name 3-methylidene-6-propan-2-ylcyclohexene. In the local archive, angelica root cites beta-phellandrene at 10.1%, with additional occurrence across dill weed Oregon, elemi, ginger fresh, parsley herb Oregon, pine dwarf, tangerine, and yuzu records. Primary enzyme studies show beta-phellandrene can be produced from GPP in lavender and from NPP in tomato glandular trichomes, highlighting route variation across plants.
Aroma and practical use
- Use the recorded peppery, minty, citrus-like, terpenic, citrus descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Review the flagged use concerns across every contributing oil and the selected dilution.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
A lavender terpene-synthase study reported that recombinant LaβPHLS converted GPP and NPP into beta-phellandrene as the major product, with strongest transcript abundance in young leaves where the compound is produced.
This is one of the clearest constituent-specific identity and biosynthesis papers for beta-phellandrene.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
A tomato glandular-trichome study found that phellandrene synthase 1 used neryl diphosphate rather than geranyl diphosphate to produce beta-phellandrene as the major product.
The paper is useful mechanistically because it shows plant-dependent precursor differences in monoterpene biosynthesis.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
A 2017 genotoxicity paper reported DNA-damage and mutation signals for beta-phellandrene in comet and Ames assays, while micronucleus and chromosome-aberration tests were negative at chromosome level.
This is mixed safety evidence and should be represented conservatively rather than collapsed into a simple safe or unsafe label.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A constituent-screening cholinesterase paper reported selective AChE inhibition for beta-phellandrene with an IC50 of 120.2 microg/mL.
The activity is relatively modest and comes from an in vitro screen, so it should not be interpreted as practical neurologic efficacy.
This experimental finding does not establish benefit, dose or safety in people using this blend.
Use concerns and concentration limits
Sensitization concernFlagged
Flagged in the constituent reference; assess the source, route and finished-product concentration.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernFlagged
Flagged in the constituent reference; assess the source, route and finished-product concentration.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
No numeric constituent-specific use limit is available here. Missing is not an unrestricted-use clearance.
A 2024 RIFM fragrance safety assessment exists for beta-phellandrene and is the strongest human-relevant safety source located in this pass.
The source assessment applies to its specified exposure and preparation; this entry is not an unrestricted-use clearance.
No direct public citation is attached to this entry.
A 2017 constituent-specific genotoxicity paper reported mixed findings, including positive comet and Ames signals but negative micronucleus and chromosome-aberration results.
This experimental finding does not establish benefit, dose or safety in people using this blend.
No direct public citation is attached to this entry.
Direct human clinical efficacy studies for isolated beta-phellandrene were not verified in this pass.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
These are research candidates recorded in the interaction matrix. They do not add a proven-amplification bonus to the score.
gamma-TerpineneAmplification candidate
Candidate in the research matrix. A coefficient alone does not establish amplification at the dose, route or goal of your blend; no proven amplification is inferred from this row.
in vitro mechanistic · antioxidant
No source citation attached.
Read gamma-Terpinene report →How the effects were investigated
monoterpene_synthase_product_from_gpp_or_npp
Characterized plant enzymes produce beta-phellandrene from isoprenoid precursors, with lavender synthase favoring GPP and tomato trichome synthase using NPP as precursor.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
weak_direct_cholinesterase_inhibition_signal
One constituent-screening paper reported selective AChE inhibition for beta-phellandrene, but the activity was modest and remains a preliminary in vitro signal.
This experimental finding does not establish benefit, dose or safety in people using this blend.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (6)
- This pass did not verify human clinical efficacy evidence for isolated beta-phellandrene.
- Most direct constituent studies are biosynthesis or safety oriented rather than wellness oriented.
- The public safety picture is stronger than the public efficacy picture, and the genotoxicity literature is not fully one-directional.
- No constituent-specific numeric dermal reference is available here.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.
- Interaction candidates lack an attached source citation and remain unqualified.